New COVID vaccine candidate passes first safety check in small trial
NCT ID NCT04839146
First seen Feb 20, 2026 · Last updated Apr 29, 2026 · Updated 5 times
Summary
This early-stage trial tested a new COVID-19 vaccine called ABNCoV2 in 45 healthy adults who had never had COVID-19. The goal was to see if the vaccine is safe and to measure the immune response it produces. Participants received two doses, with or without an immune booster (adjuvant), to find the best balance of safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Radboud univserity medical center
Nijmegen, Gelderland, 6525GA, Netherlands
Conditions
Explore the condition pages connected to this study.